The Administration of Lemborexant at Admission is Not Associated with Inpatient Falls: A Multicenter Retrospective Observational Study
- PMID: 38559594
- PMCID: PMC10979668
- DOI: 10.2147/IJGM.S452278
The Administration of Lemborexant at Admission is Not Associated with Inpatient Falls: A Multicenter Retrospective Observational Study
Abstract
Purpose: There has been no large-scale investigation into the association between the use of lemborexant, suvorexant, and ramelteon and falls in a large population. This study, serving as a pilot investigation, was aimed at examining the relationship between inpatient falls and various prescribed hypnotic medications at admission.
Patients and methods: This study was a sub-analysis of a multicenter retrospective observational study conducted over a period of 3 years. The target population comprised patients aged 20 years or above admitted to eight hospitals, including chronic care, acute care, and tertiary hospitals. We extracted data on the types of hypnotic medications prescribed at admission, including lemborexant, suvorexant, ramelteon, benzodiazepines, Z-drugs, and other hypnotics; the occurrence of inpatient falls during the hospital stay; and patients' background information. To determine the outcome of inpatient falls, items with low collinearity were selected and included as covariates in a forced-entry binary logistic regression analysis.
Results: Overall, 150,278 patients were included in the analysis, among whom 3,458 experienced falls. The median age of the entire cohort was 70 years, with men constituting 53.1%. Binary logistic regression analysis revealed that the prescription of lemborexant, suvorexant, and ramelteon at admission was not significantly associated with inpatient falls.
Conclusion: The administration of lemborexant, suvorexant, and ramelteon at admission may not be associated with inpatient falls.
Keywords: hypnotics; in-hospital falls; lemborexant; risk factor.
© 2024 Hirata et al.
Conflict of interest statement
Masaki Tago is supported by grants from the Japan Society for the Promotion of Science, JSPS KAKENHI (Grant Number JP18K17322 and JP21H03166). Naoko E. Katsuki is supported by grants from the Japan Society for the Promotion of Science, JSPS KAKENHI (Grant Number JP23K16257). The sponsor of the study had no role in the preparation of the manuscript. The authors report no other conflicts of interest in this work.
Similar articles
-
Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study.Cureus. 2024 Oct 8;16(10):e71049. doi: 10.7759/cureus.71049. eCollection 2024 Oct. Cureus. 2024. PMID: 39512953 Free PMC article.
-
[Association Suvorexant and Ramelteon Use with the Risk of Falling: A Retrospective Case-control Study].Yakugaku Zasshi. 2020;140(8):1041-1049. doi: 10.1248/yakushi.20-00018. Yakugaku Zasshi. 2020. PMID: 32741862 Japanese.
-
Risk of falls associated with non-GABAergic hypnotics and benzodiazepines in hospitalized patients.Gen Hosp Psychiatry. 2025 May-Jun;94:10-15. doi: 10.1016/j.genhosppsych.2025.02.004. Epub 2025 Feb 13. Gen Hosp Psychiatry. 2025. PMID: 39955807
-
Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?Australas Psychiatry. 2022 Aug;30(4):530-532. doi: 10.1177/10398562221092310. Epub 2022 May 1. Australas Psychiatry. 2022. PMID: 35491942 Review.
-
Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.Front Psychiatry. 2022 Dec 12;13:1070522. doi: 10.3389/fpsyt.2022.1070522. eCollection 2022. Front Psychiatry. 2022. PMID: 36578296 Free PMC article.
Cited by
-
Association Between Hypnotics, Accidents, and Injuries: A Study Based on the Adverse Drug Event Reporting Database in Japan.In Vivo. 2025 Jan-Feb;39(1):433-439. doi: 10.21873/invivo.13846. In Vivo. 2025. PMID: 39740920 Free PMC article.
-
Association between ramelteon use and risk of fragility fractures: A retrospective cohort study.Arch Osteoporos. 2025 Jul 15;20(1):95. doi: 10.1007/s11657-025-01582-9. Arch Osteoporos. 2025. PMID: 40665152
References
LinkOut - more resources
Full Text Sources